Fusion Pharmaceuticals Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FUSN research report →
Range $6 – $21
Price Chart
About the company
Fusion Pharmaceuticals Inc. is a clinical-stage oncology enterprise focused on creating precise radiopharmaceutical therapies. The company utilizes its groundbreaking Targeted Alpha Therapies platform, which incorporates its exclusive Fast-Clear linker technology.
- CEO
- John F. Valliant
- IPO
- 2020
- Employees
- 101
- HQ
- Hamilton, ON, CA
Get TickerSpark's AI analysis on FUSN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.83B
- P/E
- -14.86
- PEG
- -0.42
- P/S
- 886.38
- P/B
- 6.36
- EV/EBITDA
- -20.79
- Div Yield
- 0.00%
- Gross Margin
- 34.96%
- Op Margin
- -4798.45%
- Net Margin
- -4588.83%
- ROE
- -49.34%
- ROIC
- -36.25%
Latest fiscal year · YoY change
- Revenue
- $2.07M+41.5%
- Gross Profit
- $723.00K+101.3%
- Op Income
- $-99,232,000
- Net Income
- $-94,897,000-8.3%
- EPS
- $-1.45+27.5%
- OCF Growth
- -11.6%
- FCF Growth
- -13.6%
- 52W High
- $21.60
- 52W Low
- $2.31
- 50D MA
- $21.39
- 200D MA
- $10.42
- Beta
- -0.69
- RSI (14)
- 69
- Avg Volume
- 1.97M
No earnings-call transcripts are available for FUSN yet.
- Free Float
- 72.4%
- Shares Outstanding
- 85.06M
- Float Shares
- 61.58M
of shares held by institutions
83 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Weiss Multi-Strategy Advisers LLC | 172.36K | ▲ 172.36K |
| Tekla Capital Management LLC | 43.39K | 0 |
| Credit Suisse AG/ | 40.94K | ▲ 40.94K |
| Cutler Group LLC / Ca | 8.60K | ▲ 7.50K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 4, 24 | Bitetti Teresa Marie | sell | 34,000 |
| Jun 4, 24 | GANNON STEVEN | sell | 56,400 |
| Jun 4, 24 | GANNON STEVEN | sell | 17,000 |
| Jun 4, 24 | GANNON STEVEN | sell | 17,000 |
| Jun 4, 24 | GANNON STEVEN | sell | 17,000 |
| Jun 4, 24 | GANNON STEVEN | sell | 141,011 |
| Jun 4, 24 | GANNON STEVEN | sell | 30,000 |
| Jun 4, 24 | Valliant John | sell | 192,200 |
| Jun 4, 24 | Valliant John | sell | 336,000 |
| Jun 4, 24 | Valliant John | sell | 500,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our FUSN coverage
Recent articles, reports, and earnings notes.
No research on FUSN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate FUSN report →Trump administration backs nuclear fusion — as a company tied to Trump invests in it
marketwatch.com · May 18
AstraZeneca to Buy Fusion Pharmaceuticals for Up to $2.4B as Firm Expands Cancer Pipeline
investopedia.com · Feb 20
Acquisition of Fusion Pharmaceuticals Completed
prnewswire.com · Jun 4
Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement
prnewswire.com · May 31
Fusion Pharmaceuticals Shareholders Approve Acquisition by AstraZeneca
prnewswire.com · May 29
Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer
prnewswire.com · May 9
FUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fusion Pharmaceuticals Inc. - FUSN
businesswire.com · May 9
Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates
prnewswire.com · May 7
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.